Smith & Nephew plc (NYSE:SNN) Receives Consensus Rating of “Hold” from Brokerages

Smith & Nephew plc (NYSE:SNN) has received a consensus rating of “Hold” from the five ratings firms that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company.

Separately, StockNews.com raised shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a report on Friday, March 15th.

Smith & Nephew Stock Performance

Shares of Smith & Nephew stock opened at $24.36 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.77 and a quick ratio of 0.72. The company’s fifty day moving average price is $26.26 and its two-hundred day moving average price is $25.98. Smith & Nephew has a 52-week low of $21.52 and a 52-week high of $33.08.

Smith & Nephew Dividend Announcement

The company also recently announced a semi-annual dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Tuesday, April 2nd will be issued a $0.462 dividend. This represents a dividend yield of 2.8%. The ex-dividend date is Monday, April 1st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in SNN. American Century Companies Inc. lifted its position in Smith & Nephew by 343.5% during the 3rd quarter. American Century Companies Inc. now owns 2,364,037 shares of the medical equipment provider’s stock worth $58,557,000 after buying an additional 1,830,965 shares in the last quarter. Brandes Investment Partners LP bought a new position in shares of Smith & Nephew during the 4th quarter worth approximately $29,884,000. Scharf Investments LLC grew its stake in shares of Smith & Nephew by 20.5% during the 4th quarter. Scharf Investments LLC now owns 2,980,334 shares of the medical equipment provider’s stock worth $81,304,000 after acquiring an additional 506,474 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Smith & Nephew during the 3rd quarter worth approximately $8,174,000. Finally, Envestnet Asset Management Inc. grew its stake in shares of Smith & Nephew by 133.6% during the 3rd quarter. Envestnet Asset Management Inc. now owns 539,491 shares of the medical equipment provider’s stock worth $13,363,000 after acquiring an additional 308,559 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.